CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease
about
Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patientsPharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health TransitionIdentification of potential candidate genes for hypertensive nephropathy based on gene expression profile.Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control.Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.CYP3A5 polymorphism, amlodipine and hypertension.Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study.Ancestry-Adjusted Vitamin D Metabolite Concentrations in Association with Cytochrome 3A (CYP3A) Polymorphisms.Comparative effectiveness of antihypertensive drugs prescribed in Ethiopian healthcare practice: A pilot prospective, randomized, open label study
P2860
Q34747512-F3122350-C64D-46E5-BF5D-5AB672FEC5F8Q35662487-5737CB4B-CEB6-487A-A657-627BE20BA622Q36105822-EF5089BC-4C50-4B97-B9D1-D0B3436D1942Q36166668-5BA2D611-681C-4D71-A537-5B310F8E2CB9Q36285918-CEC6E72B-7EC8-4022-8AFF-D2B88B60A9C3Q36750899-402397D2-1BC2-43F4-8ACB-A2115ACA47A2Q37009025-BB8168A8-70A9-4F1C-BF3D-C222BF2AF35FQ37207789-11F216DD-6BF8-454E-9D63-766DE04443F3Q38122295-52563424-808B-4D35-8F3A-C708FA0AD7B1Q42723097-8BF84E9F-FA34-4F0A-A97E-F19992322E11Q43463239-00E5E3F5-C15E-48A3-989E-643887C8ABBAQ50548159-EF8AB20C-138B-4E17-B017-A224964BD200Q58752251-162C8CD8-2924-42F4-8758-F81F18959DAF
P2860
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
CYP3A4 and CYP3A5 polymorphism ...... rly hypertensive renal disease
@ast
CYP3A4 and CYP3A5 polymorphism ...... rly hypertensive renal disease
@en
type
label
CYP3A4 and CYP3A5 polymorphism ...... rly hypertensive renal disease
@ast
CYP3A4 and CYP3A5 polymorphism ...... rly hypertensive renal disease
@en
prefLabel
CYP3A4 and CYP3A5 polymorphism ...... rly hypertensive renal disease
@ast
CYP3A4 and CYP3A5 polymorphism ...... rly hypertensive renal disease
@en
P2093
P2860
P356
P1476
CYP3A4 and CYP3A5 polymorphism ...... rly hypertensive renal disease
@en
P2093
AASK Study Investigators
Daniel T O'Connor
Erin P Garcia
Erin Richard
Gabriel Contreras
George L Bakris
Jackson Wright
John Alcaraz
John P Middleton
Keith C Norris
P2860
P304
P356
10.1159/000258688
P577
2009-11-12T00:00:00Z